Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms. The company was founded in 2000 and is based in New York, New York.
IPO Year:
Exchange: AMEX
Website: actiniumpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/7/2024 | $16.00 → $2.00 | Buy → Neutral | B. Riley Securities |
| 5/14/2024 | $25.00 | Overweight | Stephens |
| 9/6/2023 | $11.60 | Buy | HSBC Securities |
| 2/21/2023 | Outperform → Mkt Perform | William Blair | |
| 9/8/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 8/25/2022 | $16.00 | Buy | B. Riley Securities |
| 8/3/2021 | $57.00 → $45.00 | Buy | HC Wainwright & Co. |
Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approachesSIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significanceIomab-B was well tolerated in the older, heavily pretreated relapsed/refractory AML patients with active disease enrolled in the SIERRA trialActinium to seek strategic partner for Iomab-B for further development in the U.S. following completion of interactions with FDA for additional head-to-head clinical trial to demonstrate overall survival benefitNEW YORK, Sept.
FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpointAdditional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support a BLA filingActinium to request a meeting with the FDA to further discuss specifics of additional trialActinium will seek strategic partner for Iomab-B in the U.S. following completion of FDA interactions and focus development efforts on Actimab-A, Iomab-ACT and preclinical programsNEW YORK, Aug. 5, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the devel
- Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs - Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined immunodeficiency disease, β-thalassemia and Fanconi's anemia NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the issuance of U.S. Patent No. 11,912,780 titled, "Anti-CD45-B
- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease patients - Initial trial focused on conditioning for bone marrow transplant intended to inform subsequent gene therapy conditioning study and provide broader access to cellular therapy for sickle cell patients NEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antib
Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemiaIomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with acute myeloid leukemiaNEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Company will participate in the 3rd Annual Targeted Radiopharmaceuticals Summit U
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring Actinium Pharmaceuticals, Inc. (NYSE:ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies.Read the full article on Investorideas https://www.investorideas.com/News/2024/biotech/06180Treatment-of-Blood-Cancers.aspApproximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma. Approximately ev
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors - Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy - Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors NEW YORK, June 17, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial - Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial NEW YORK, June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at
- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia - Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and venetoclax treated patients - SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination NEW YORK, June 11, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherap
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutationIomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% access to bone marrow transplantNovel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indicationsNEW YORK, June 10, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiothera
Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, today announced multiple updates on its R&D capabilities. Actinium recently completed expansion of its New York City based research facilities to focus on the development of targeted radiotherapies for solid tumors and blood cancers and to investigate novel radiotherapy combinations with checkpoint inhibitors. Actinium has more than doubled its laboratory footprint and expanded its R&D capabilities. In addition to infrastructure, Actinium has increased its R&D team to include scientists with e
NEW YORK, March 3, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the appointment of Mark Kubik, MBA to the position of Chief Business Officer (CBO). In this role, Mr. Kubik will be responsible for leading the Company's business development activities including collaboration and partnership activities as well as portfolio and alliance management. He will focus on leveraging Actinium's AWE technology platform, which encompasses Actinium's strong intellectual property portfolio, know-how and research capabilities, and pipeline of ARCs or antibody radiation conjugates to drive business development activity. Mark joins Actinium from OncoIm
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium's CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia ("R/R AML"). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to work
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
SC 13G/A - Actinium Pharmaceuticals, Inc. (0001388320) (Subject)
B. Riley Securities downgraded Actinum Pharma from Buy to Neutral and set a new price target of $2.00 from $16.00 previously
Stephens initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $25.00
HSBC Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $11.60
William Blair downgraded Actinum Pharma from Outperform to Mkt Perform
Cantor Fitzgerald initiated coverage of Actinum Pharma with a rating of Overweight and set a new price target of $20.00
B. Riley Securities initiated coverage of Actinum Pharma with a rating of Buy and set a new price target of $16.00
HC Wainwright & Co. reiterated coverage of Actinium Pharmaceuticals with a rating of Buy and set a new price target of $45.00 from $57.00 previously
HC Wainwright & Co. reiterated coverage of Actinium Pharmaceuticals with a rating of Buy and set a new price target of $57.00 from $65.00 previously
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
S-8 - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
10-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
EFFECT - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
S-3/A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
ARS - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
DEF 14A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
Collaboration With Columbia University Aims To Broaden Access To Cellular Therapies And Inform Gene Therapy Conditioning Study
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors- Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy- Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial- Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trialNEW YORK, June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at t
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutationIomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% access to bone marrow transplantNovel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indicationsNEW YORK, June 10, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiothera
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $50 price target.
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial - Long-term efficacy results in older patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trial
Stephens & Co. analyst Sudan Loganathan initiates coverage on Actinium Pharma (AMEX:ATNM) with a Overweight rating and announces Price Target of $25.
- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey- Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment- Novel linker technology supports Actinium's Antibody Radiation Conjugate pipeline expansion in solid tumor indications
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm - In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients - Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 - Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover - Iomab-B was
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,
- Full Iomab-B SIERRA data set to be presented in late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 - Company to host conference call and webcast on Saturday, February 18, 2023, at 6:00 PM EST - SIERRA trial met primary endpoint with high statistical significance (p<0.0001) - Company to host Iomab-B KOL event with Dr. Sergio Giralt of Memorial Sloan Kettering Cancer Center at 8:00 AM EST on February 28, 2023 NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that data from its pivotal Phase 3 SIERRA trial of Iomab-B have been accepted as
- Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of <0.0001 NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was conducted in patients 55 years of age or older who had active disease (relapsed or refractory AML). The SIERRA trial is a randomized, multi-center, controlled study which compared Iomab-B as a
INDIANAPOLIS--(BUSINESS WIRE)--Anthem, Inc. (NYSE: ATNM) today announced that the company has entered into an agreement to acquire myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors. myNEXUS delivers integrated clinical support services for approximately 1.7 million Medicare Advantage members across 20 states. “Providing timely care for members in their homes allows for both excellent personalized care as well as the comfort of being in preferred environments,” said Prakash Patel, M.D., Anthem Executive Vice President, and President, Anthem Diversified Business Group. “Bringing the right level of whole person care into the home has been de